216 related articles for article (PubMed ID: 22360729)
1. PAI-1, progress in understanding the clinical problem and its aetiology.
Iwaki T; Urano T; Umemura K
Br J Haematol; 2012 May; 157(3):291-8. PubMed ID: 22360729
[TBL] [Abstract][Full Text] [Related]
2. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
3. Use of mouse models to study plasminogen activator inhibitor-1.
Declerck PJ; Gils A; De Taeye B
Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
[TBL] [Abstract][Full Text] [Related]
4. The role of fibrinolytic genes and proteins in the development of allograft vascular disease.
Benza RL; Passineau MJ; Anderson PG; Barchue JP; George JF
J Heart Lung Transplant; 2011 Aug; 30(8):935-44. PubMed ID: 21652221
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.
Wind T; Hansen M; Jensen JK; Andreasen PA
Biol Chem; 2002 Jan; 383(1):21-36. PubMed ID: 11928815
[TBL] [Abstract][Full Text] [Related]
6. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
7. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E
FASEB J; 2003 Oct; 17(13):1904-6. PubMed ID: 12897066
[TBL] [Abstract][Full Text] [Related]
8. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans.
Iwaki T; Tanaka A; Miyawaki Y; Suzuki A; Kobayashi T; Takamatsu J; Matsushita T; Umemura K; Urano T; Kojima T; Terao T; Kanayama N
J Thromb Haemost; 2011 Jun; 9(6):1200-6. PubMed ID: 21486382
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA
Circ Res; 2004 Sep; 95(6):637-44. PubMed ID: 15297377
[TBL] [Abstract][Full Text] [Related]
10. Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1.
Kim JW; Lee SH; Ko HM; Kwon KJ; Cho KS; Choi CS; Park JH; Kim HY; Lee J; Han SH; Ignarro LJ; Cheong JH; Kim WK; Shin CY
Neurochem Int; 2011 Feb; 58(3):423-33. PubMed ID: 21193004
[TBL] [Abstract][Full Text] [Related]
11. Fracture healing in mice deficient in plasminogen activator inhibitor-1.
Rundle CH; Wang X; Wergedal JE; Mohan S; Lau KH
Calcif Tissue Int; 2008 Oct; 83(4):276-84. PubMed ID: 18820962
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
13. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
14. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
Gils A; Declerck PJ
Thromb Haemost; 2004 Mar; 91(3):425-37. PubMed ID: 14983217
[TBL] [Abstract][Full Text] [Related]
15. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
16. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin.
Declerck PJ; Gils A
Semin Thromb Hemost; 2013 Jun; 39(4):356-64. PubMed ID: 23504606
[TBL] [Abstract][Full Text] [Related]
17. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
Mavri A; Alessi MC; Juhan-Vague I
J Intern Med; 2004 Apr; 255(4):448-56. PubMed ID: 15049879
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway.
Kwak SH; Wang XQ; He Q; Fang WF; Mitra S; Bdeir K; Ploplis VA; Xu Z; Idell S; Cines D; Abraham E
Thromb Haemost; 2006 May; 95(5):829-35. PubMed ID: 16676075
[TBL] [Abstract][Full Text] [Related]
19. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
Cederqvist K; Sirén V; Petäjä J; Vaheri A; Haglund C; Andersson S
Pediatrics; 2006 Apr; 117(4):1226-34. PubMed ID: 16585319
[TBL] [Abstract][Full Text] [Related]
20. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
